{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:42:55Z","timestamp":1768689775027,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T00:00:00Z","timestamp":1395100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1741-7015-12-48","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T16:05:02Z","timestamp":1395158702000},"source":"Crossref","is-referenced-by-count":16,"title":["Biologics, cardiovascular effects and cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Nemanja","family":"Damjanov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,18]]},"reference":[{"key":"941_CR1","first-page":"1213","volume":"32","author":"LT Jacobsson","year":"2005","unstructured":"Jacobsson LT, Turesson C, G\u00fclfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005, 32: 1213-1218.","journal-title":"J Rheumatol"},{"key":"941_CR2","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007, 56: 2905-2912. 10.1002\/art.22809.","journal-title":"Arthritis Rheum"},{"key":"941_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1196\/annals.1422.036","volume":"1108","author":"Z Szekanecz","year":"2007","unstructured":"Szekanecz Z, Kerekes G, Der H, Sandor Z, Szabo Z, Vegvari A, Simkovics E, Soos L, Szentpetery A, Besenyei T, Sz\u00fccs G, Sz\u00e1nt\u00f3 S, Tam\u00e1si L, Szegedi G, Shoenfeld Y, Solt\u00e9sz P: Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci. 2007, 1108: 349-358. 10.1196\/annals.1422.036.","journal-title":"Ann N Y Acad Sci"},{"key":"941_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","volume":"5","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Kerekes G, Soltesz P: Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009, 5: 677-684. 10.1038\/nrrheum.2009.219.","journal-title":"Nat Rev Rheumatol"},{"key":"941_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/art.20407","volume":"51","author":"C Gonzalez-Juanatey","year":"2004","unstructured":"Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 2004, 51: 447-450. 10.1002\/art.20407.","journal-title":"Arthritis Rheum"},{"key":"941_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10067-007-0803-y","volume":"27","author":"S Bosello","year":"2008","unstructured":"Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G: TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol. 2008, 27: 833-839. 10.1007\/s10067-007-0803-y.","journal-title":"Clin Rheumatol"},{"key":"941_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/rheumatology\/kem089","volume":"46","author":"F Del Porto","year":"2007","unstructured":"Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, Podesta E, Mitterhofer AP, D'Amelio R: Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2007, 46: 1111-1115. 10.1093\/rheumatology\/kem089.","journal-title":"Rheumatology (Oxford)"},{"key":"941_CR8","first-page":"147","volume":"13","author":"G Kerekes","year":"2011","unstructured":"Kerekes G, Soltesz P, Szucs G, Szamosi S, Der H, Szabo Z, Csathy L, Vancsa A, Szodoray P, Szegedi G, Szekanecz Z: Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J. 2011, 13: 147-152.","journal-title":"Isr Med Assoc J"},{"key":"941_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","volume":"41","author":"AM van Sijl","year":"2011","unstructured":"van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT: The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum. 2011, 41: 393-400. 10.1016\/j.semarthrit.2011.04.003.","journal-title":"Semin Arthritis Rheum"},{"key":"941_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE: Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011, 70: 482-487. 10.1136\/ard.2010.135871.","journal-title":"Ann Rheum Dis"},{"key":"941_CR11","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/ar2404","volume":"10","author":"AL Smitten","year":"2008","unstructured":"Smitten AL, Simon TA, Hochberg MC, Suissa S: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008, 10: R45-10.1186\/ar2404.","journal-title":"Arthritis Res Ther"},{"key":"941_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011, 20: 119-130. 10.1002\/pds.2046.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"941_CR13","first-page":"756","volume":"30","author":"P Le Blay","year":"2012","unstructured":"Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B: Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol. 2012, 30: 756-764.","journal-title":"Clin Exp Rheumatol"},{"key":"941_CR14","doi-asserted-by":"publisher","first-page":"f1939","DOI":"10.1136\/bmj.f1939","volume":"346","author":"P Raaschou","year":"2013","unstructured":"Raaschou P, Simard JF, Holmqvist M, Askling J, ARTIS Study Group: Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013, 346: f1939-10.1136\/bmj.f1939.","journal-title":"BMJ"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-12-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-12-48\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-12-48","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T19:14:58Z","timestamp":1468869298000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-12-48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,18]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-12-48","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,18]]},"article-number":"48"}}